HC Wainwright Reaffirms Buy Rating for Altimmune (NASDAQ:ALT)
Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 106.54% from the company’s current price. A […]
Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 106.54% from the company’s current price. A […]
